Company Developing Cerenkov Luminescence Imaging Technologies Raises Funding for Innovative Products

A developer of novel imaging technologies has received GBP 2 million in funding to help bring its lead products to market in 2015.

The products, currently in clinical trials at Guy's Hospital (Great Maze Pond, London, United Kingdom) can help surgeons detect cancer in real-time during surgery using optical detection of Positron Emission Tomography (PET) tracer, and will reduce the high rate of repeat operations especially in breast and prostate cancer patients.

In the United Kingdom one in four women that have surgery for early-stage breast cancer need a second operation. Using current techniques surgeons are not able to accurately detect tiny cancerous deposits during an operation. The undetected cancerous tissues remain and need to be removed in one or more follow-up operations.

The LightPath specimen analyzer and the EnLight molecular imaging fiberscope were developed by Lightpoint Medical (London, United Kingdom).

Dr. David Tuch, CEO of Lightpoint Medica said: “The level of investment we have raised reflects the real clinical demand for this technology, and therefore its enormous market potential. The current rate of re-operations comes with a high cost to patient well-being and healthcare budgets, and we are very pleased that the funding will help bring our products to people who need them.”

Related Links:
Guy's Hospital
Lightpoint Medical